Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 39

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 39
---
)
to exceed 4.99% (or, upon election of holder, 9.99%) of the combined voting power of all of our securities outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. As
a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it would be financially
beneficial for you to do so. In such a circumstance, you could seek to sell your Pre-Funded Warrants to realize value, but you may be
unable to do so in the absence of an established trading market and due to applicable transfer restrictions.

| 24 |

<div align='center'>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and the documents
incorporated herein by reference contain forward-looking statements. The forward-looking statements are contained principally in the
sections entitled “Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” and “Business” in this prospectus or the documents incorporated herein by reference. These
statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other
factors which may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements
about:

| · | our ability to successfully                                                                                            
 commercialize our products and technology, including our Hemopurifier;                                                 |
| · | our ability to raise additional                                                                                        
 capital to meet our working capital needs;                                                                             |
| · | the timing and results                                                                                                 
 of future clinical trials;                                                                                             |
| · | our ability to successfully                                                                                            
 complete our clinical trials;                                                                                          |
| · | our ability to identify                                                                                                
 and work with large-scale contracts with medical device manufacturers;                                                 |
| · | our ability to manufacture                                                                                             
 the Hemopurifier;                                                                                                      |
| · | the impact of inflation,                                                                                               
 recent bank failures and military conflicts, as well as related political and economic responses on our business;      |
| · | our ability to attract                                                                                                 
 and retain executive management and directors;                                                                         |
| · | the regulatory landscape                                                                                               
 for our products, domestically and internationally and our ability to comply with changing government regulations;     |
| · | our ability